Stockreport

 Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com
PDF  – Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 –– Potential for ECOSPOR III to be a single pivotal study supporting product registratio [Read more]